Predictive Value of FOLFOX-Based Regimen, Long Interval, Hemoglobin Levels and Clinical Negative Nodal Status, and Postchemoradiotherapy CEA Levels for Pathological Complete Response in Patients with Locally Advanced Rectal Cancer after Neoadjuvant Chemoradiotherapy

Table 1

Clinical characteristics of patients with locally advanced rectal cancer after trimodality treatment.

	pCR (%)	Non-pCR (%)	value
All patients, no.	56 (23.7)	180 (76.3)	—
Gender			0.4139
Male	34 (22.1)	120 (77.9)
Female	22 (26.8)	60 (73.2)
Age at diagnosis			0.3590
≤60	21 (20.8)	80 (79.2)
>60	35 (25.9)	100 (74.1)
Location of tumor			0.1564
Upper	18 (19.0)	77 (81.0)
Middle/low	38 (27.0)	103 (73.0)
Grade			0.0577
Well differentiated	0 (0)	16 (100)
Moderate differentiated	53 (25.0)	159 (75.0)
Poor differentiated	3 (37.5)	5 (62.5)
Clinical T stage			0.1964
T2	4 (30.8)	9 (69.2)
T3	47 (25.5)	137 (74.5)
T4	5 (12.8)	34 (87.2)
Clinical N stage			0.0202
N0	14 (39.0)	22 (61.0)
N+	42 (21.0)	158 (79.0)
Radiation dose (cGy)			0.0772
≤4500	5 (11.4)	39 (88.6)
>5000	51 (88.6)	141 (11.4)
Chemotherapy
FOLFOX	40 (28.4)	101 (71.6)	0.0412
Fluoropyridine	16 (16.8)	79 (83.2)
Cycles of pre-OP chemotherapy			0.5215
<7	39 (25)	117 (75)
≥7	17 (21.3)	63 (78.7)
Pre-CRT CEA (ng/mL)			0.0674
≤5	40 (27.8)	104 (72.2)
>5	16 (17.4)	76 (82.6)
Anemia during CRT			0.0159
Hb (g/dL) > 10	47 (28.0)	121 (72.0)
Hb (g/dL) ≤ 10	9 (13.2)	59 (86.8)
Leukopenia during CRT			0.1113
WBC > 3000 (/μL)	29 (20.3)	114 (79.7)
WBC ≤ 3000 (/μL)	27 (29.4)	65 (70.6)
RT to surgery interval			0.0081
≤8 weeks	11 (13.6)	70 (86.4)
>8 weeks	45 (29.0)	110 (71.0)
ycT stage			0.0734
T0	4 (33.3)	8 (66.7)
T1	1 (11.1)	9 (88.9)
T2	8 (32)	17 (68)
T3	35 (26.1)	99 (73.9)
T4	8 (14.3)	48 (85.7)
ycN stage			0.1515
N0	30 (20.5)	116 (79.5)
N+	26 (28.9)	64 (71.1)
Post-CRT CEA (ng/mL)			0.0285
≤2	9 (45)	11 (55)
>2	47 (21.8)	169 (78.2)

CEA, carcinoembryonic antigen; CRT, chemoradiation therapy; FOLFOX, fluorouracil, leucovorin, and oxaliplatin; Hb, hemoglobin; OP, operative; pCR, pathological complete response; RT, radiation therapy; WBC, white blood cell; ycT stage: clinical tumor stage after chemoradiotherapy; ycN stage: clinical nodal stage after chemoradiotherapy. Fisher’s exact test.